ACIU - AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 | Benzinga
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
- Three oral presentations at the Alzheimer's Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626
Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer's Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024.
Presentation details (all times are EDT)
Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer
Date: Monday, July 29, 2024 | 2:50 PM – 3:00 PM
Location: Hall A - Pennsylvania Convention Center
Presenter: Tamara Seredenina, PhD (AC Immune)
Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies
Date: Tuesday, July 30, 2024 | 9:40 AM – 9:50 PM
Location: 201 ABC - Pennsylvania Convention Center
Presenter: Emma Fiorini, PhD (AC Immune)
A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)
Date: Wednesday, July 31, 2024 | 8:07 AM – 8:14 AM
Location: 118 ABC - Pennsylvania Convention Center
Presenter: Madiha Derouazi, PhD (AC Immune)
Poster details
#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer's disease and Down Syndrome-related Alzheimer's disease
Date: Tuesday, July 30, 2024 | 8:00 AM – 4:15 PM